Premium
Global standardization measurement of cerebral spinal fluid for Alzheimer's disease: An update from the Alzheimer's Association Global Biomarkers Consortium
Author(s) -
Carrillo Maria C.,
Blennow Kaj,
Soares Holly,
Lewczuk Piotr,
Mattsson Niklas,
Oberoi Pankaj,
Umek Robert,
Vandijck Manu,
Salamone Salvatore,
Bittner Tobias,
Shaw Leslie M.,
Stephenson Diane,
Bain Lisa,
Zetterberg Henrik
Publication year - 2013
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2012.11.003
Subject(s) - standardization , biomarker , harmonization , medicine , cerebrospinal fluid , alzheimer's disease , disease , intensive care medicine , pathology , computer science , biology , biochemistry , physics , acoustics , operating system
Recognizing that international collaboration is critical for the acceleration of biomarker standardization efforts and the efficient development of improved diagnosis and therapy, the Alzheimer's Association created the Global Biomarkers Standardization Consortium (GBSC) in 2010. The consortium brings together representatives of academic centers, industry, and the regulatory community with the common goal of developing internationally accepted common reference standards and reference methods for the assessment of cerebrospinal fluid (CSF) amyloid β42 (Aβ42) and tau biomarkers. Such standards are essential to ensure that analytical measurements are reproducible and consistent across multiple laboratories and across multiple kit manufacturers. Analytical harmonization for CSF Aβ42 and tau will help reduce confusion in the AD community regarding the absolute values associated with the clinical interpretation of CSF biomarker results and enable worldwide comparison of CSF biomarker results across AD clinical studies.